{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:12:49Z","timestamp":1790712769906,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bexarotene has been established as an effective therapeutic agent for mycosis fungoides (MF), both in early, refractory disease and in advanced stages. It has a predictable, albeit significant, metabolic toxicity profile, raising concerns regarding long-term cardiovascular safety. We conducted a retrospective cohort study utilizing TriNetX to identify adults with MF. Patients were stratified by bexarotene exposure and 1:1 propensity score matched (PSM) for demographics, lifestyle factors, comorbidities, and baseline medications. After PSM, two well-balanced cohorts of 2,242 patients each were formed with a median follow-up of 4.0 years for both groups. Bexarotene treatment demonstrated no significant increase in the risk of the composite adapted-MACE endpoint (HR\u2009=\u20090.93, 95% CI: 0.78\u20131.11,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.425). Similarly, no significant differences were observed for individual cardiovascular components, including acute myocardial infarction (HR\u2009=\u20090.95,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.730), stroke (HR\u2009=\u20090.90,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.514), or heart failure (HR\u2009=\u20090.93,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.455). Conversely, bexarotene was associated with a significantly increased risk of metabolic and endocrine abnormalities, including hypertriglyceridemia (RR\u2009=\u20096.98,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), hypothyroidism (RR\u2009=\u20094.93,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), hyperlipidemia (RR\u2009=\u20092.18,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), and hypercholesterolemia (RR\u2009=\u20091.99,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). In the largest real-world cohort of MF patients treated with bexarotene to date, the substantial metabolic and endocrine abnormalities associated with treatment did not translate into an observed increase in cardiovascular events during a median follow-up of 4 years. These findings provide reassurance regarding the short- to intermediate-term cardiovascular profile of bexarotene when appropriate monitoring and management of lipid and thyroid abnormalities are maintained. However, longer follow-up is required to determine whether these metabolic effects influence long-term cardiovascular risk.\n                  <\/jats:p>","DOI":"10.1007\/s10238-026-02282-5","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:03:37Z","timestamp":1786363417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world cardiovascular safety profile of bexarotene for the treatment of mycosis fungoides"],"prefix":"10.1007","volume":"26","author":[{"given":"Charalampos","family":"Filippatos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Kostakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"issue":"10","key":"2282_CR1","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1111\/jdv.16325","volume":"34","author":"AE Kaufman","year":"2020","unstructured":"Kaufman AE, Patel K, Goyal K, et al. Mycosis fungoides: developments in incidence, treatment and survival. J Eur Acad Dermatol Venereol. 2020;34(10):2288\u201394. https:\/\/doi.org\/10.1111\/jdv.16325.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2282_CR2","doi-asserted-by":"publisher","unstructured":"Giordano A, Pagano L. The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist\u2019s Point of View. Mediterr J Hematol Infect Dis. 2022;14(1):e2022029. Published 2022 Mar 1. https:\/\/doi.org\/10.4084\/MJHID.2022.029","DOI":"10.4084\/MJHID.2022.029"},{"key":"2282_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/asheducation-2015.1.529","volume":"2015","author":"M Duvic","year":"2015","unstructured":"Duvic M. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and S\u00e9zary syndrome. Hematol Am Soc Hematol Educ Program. 2015;2015:529\u201344. https:\/\/doi.org\/10.1182\/asheducation-2015.1.529.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"25","key":"2282_CR4","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1182\/blood-2015-12-611830","volume":"127","author":"S Whittaker","year":"2016","unstructured":"Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and S\u00e9zary syndrome. Blood. 2016;127(25):3142\u201353. https:\/\/doi.org\/10.1182\/blood-2015-12-611830.","journal-title":"Blood"},{"issue":"6","key":"2282_CR5","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","volume":"160","author":"RA Abbott","year":"2009","unstructured":"Abbott RA, Whittaker SJ, Morris SL, et al. Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome. Br J Dermatol. 2009;160(6):1299\u2013307. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09037.x.","journal-title":"Br J Dermatol"},{"key":"2282_CR6","doi-asserted-by":"publisher","first-page":"113343","DOI":"10.1016\/j.ejca.2023.113343","volume":"195","author":"J Latzka","year":"2023","unstructured":"Latzka J, Assaf C, Bagot M, et al. EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - Update 2023. Eur J Cancer. 2023;195:113343. https:\/\/doi.org\/10.1016\/j.ejca.2023.113343.","journal-title":"Eur J Cancer"},{"issue":"14","key":"2282_CR7","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1056\/NEJM199904083401404","volume":"340","author":"SI Sherman","year":"1999","unstructured":"Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999;340(14):1075\u20139. https:\/\/doi.org\/10.1056\/NEJM199904083401404.","journal-title":"N Engl J Med"},{"issue":"5","key":"2282_CR8","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1210\/en.2008-1540","volume":"150","author":"J de Vries","year":"2009","unstructured":"de Vries J, de Haan W, Hu L, et al. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. Endocrinology. 2009;150(5):2368\u201375. https:\/\/doi.org\/10.1210\/en.2008-1540.","journal-title":"Endocrinology"},{"issue":"8","key":"2282_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1507\/endocrj.EJ23-0699","volume":"71","author":"K Manaka","year":"2024","unstructured":"Manaka K, Sato J, Hikima Y, et al. Bexarotene-induced hypothyroidism and dyslipidemia; a nation-wide study. Endocr J. 2024;71(8):777\u201387. https:\/\/doi.org\/10.1507\/endocrj.EJ23-0699.","journal-title":"Endocr J"},{"issue":"7","key":"2282_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/1346-8138.16801","volume":"50","author":"A Sanagawa","year":"2023","unstructured":"Sanagawa A, Hayakawa T, Nishida E, et al. Impact of body mass index on the severity of bexarotene-associated hypertriglyceridemia: A post hoc analysis of an open-labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T-cell lymphoma. J Dermatol. 2023;50(7):917\u201326. https:\/\/doi.org\/10.1111\/1346-8138.16801.","journal-title":"J Dermatol"},{"issue":"5","key":"2282_CR11","first-page":"581","volume":"137","author":"M Duvic","year":"2001","unstructured":"Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581\u201393.","journal-title":"Arch Dermatol"},{"issue":"1","key":"2282_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40959-020-00087-3","volume":"6","author":"S DeAngelo","year":"2020","unstructured":"DeAngelo S, Mann KI, Abdulbasit M, Ahnert A, Sundl\u00f6f DW. A case report: rapid progression of coronary atherosclerosis in a patient taking Targretin (Bexarotene). Cardiooncology. 2020;6(1):31. https:\/\/doi.org\/10.1186\/s40959-020-00087-3. Published 2020 Dec 14.","journal-title":"Cardiooncology"},{"issue":"11","key":"2282_CR13","doi-asserted-by":"publisher","first-page":"e064541","DOI":"10.1136\/bmjopen-2022-064541","volume":"13","author":"CL Morgan","year":"2023","unstructured":"Morgan CL, Durand A, McCormack T, Hughes E, Berni TR, Lahoz R. Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink. BMJ Open. 2023;13(11):e064541. https:\/\/doi.org\/10.1136\/bmjopen-2022-064541. Published 2023 Nov 29.","journal-title":"BMJ Open"},{"key":"2282_CR14","doi-asserted-by":"publisher","unstructured":"Duntas LH, Feldt-Rasmussen U. Hypothyroidism, atherosclerosis and cardiovascular risk prevention. Nat Rev Endocrinol Published online November. 2025;6. https:\/\/doi.org\/10.1038\/s41574-025-01202-z.","DOI":"10.1038\/s41574-025-01202-z"},{"key":"2282_CR15","doi-asserted-by":"publisher","unstructured":"Tentolouris A, Filippatos C, Tepetes NI, et al. GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity-Matched Real-World Analysis. Diabetes Obes Metab. Published online May. 2026;6. https:\/\/doi.org\/10.1111\/dom.70841.","DOI":"10.1111\/dom.70841"},{"key":"2282_CR16","doi-asserted-by":"publisher","unstructured":"Filippatos C, Briasoulis A, Terpos E, Fotiou D, Gavriatopoulou M. Real-World Outcomes of Mycosis Fungoides and Site-Specific Nodal Involvement: A Registry-Based Study of 25 467 Patients. Am J Hematol Published online April. 2026;16. https:\/\/doi.org\/10.1002\/ajh.70334.","DOI":"10.1002\/ajh.70334"},{"issue":"Suppl 2","key":"2282_CR17","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1038\/sj.cdd.4401533","volume":"11","author":"A Szanto","year":"2004","unstructured":"Szanto A, Narkar V, Shen Q, Uray IP, Davies PJ, Nagy L. Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ. 2004;11(Suppl 2):S126\u201343. https:\/\/doi.org\/10.1038\/sj.cdd.4401533.","journal-title":"Cell Death Differ"},{"issue":"1","key":"2282_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bbalip.2011.09.014","volume":"1821","author":"MI Dawson","year":"2012","unstructured":"Dawson MI, Xia Z. The retinoid X receptors and their ligands. Biochim Biophys Acta. 2012;1821(1):21\u201356. https:\/\/doi.org\/10.1016\/j.bbalip.2011.09.014.","journal-title":"Biochim Biophys Acta"},{"issue":"20","key":"2282_CR19","doi-asserted-by":"publisher","first-page":"e020377","DOI":"10.1161\/JAHA.120.020377","volume":"10","author":"AP Ambrosy","year":"2021","unstructured":"Ambrosy AP, Yang J, Sung SH, et al. Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. J Am Heart Assoc. 2021;10(20):e020377. https:\/\/doi.org\/10.1161\/JAHA.120.020377.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2282_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/cen.13975","volume":"91","author":"N Makita","year":"2019","unstructured":"Makita N, Manaka K, Sato J, Mitani K, Nangaku M, Iiri T. Bexarotene-induced hypothyroidism: Characteristics and therapeutic strategies. Clin Endocrinol (Oxf). 2019;91(1):195\u2013200. https:\/\/doi.org\/10.1111\/cen.13975.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2282_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1365-2133.2006.07329.x","volume":"155","author":"C Assaf","year":"2006","unstructured":"Assaf C, Bagot M, Dummer R, et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol. 2006;155(2):261\u20136. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07329.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2282_CR22","doi-asserted-by":"publisher","first-page":"luae041","DOI":"10.1210\/jcemcr\/luae041","volume":"2","author":"M Tucci","year":"2024","unstructured":"Tucci M, Galagan R, Lovre D. Successful Treatment of Bexarotene-Induced Central Hypothyroidism. JCEM Case Rep. 2024;2(4):luae041. https:\/\/doi.org\/10.1210\/jcemcr\/luae041. Published 2024 Apr 1.","journal-title":"JCEM Case Rep"},{"issue":"1","key":"2282_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000488447","volume":"11","author":"C Maminakis","year":"2018","unstructured":"Maminakis C, Whitman AC, Islam N. Bexarotene-Induced Hypertriglyceridemia: A Case Report. Case Rep Oncol. 2018;11(1):234\u20138. https:\/\/doi.org\/10.1159\/000488447. Published 2018 Apr 11.","journal-title":"Case Rep Oncol"},{"issue":"13","key":"2282_CR24","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","volume":"76","author":"MJ Domanski","year":"2020","unstructured":"Domanski MJ, Tian X, Wu CO, et al. Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk. J Am Coll Cardiol. 2020;76(13):1507\u201316. https:\/\/doi.org\/10.1016\/j.jacc.2020.07.059.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"2282_CR25","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jacc.2020.08.004","volume":"76","author":"MD Shapiro","year":"2020","unstructured":"Shapiro MD, Bhatt DL. Cholesterol-Years for ASCVD Risk Prediction and Treatment. J Am Coll Cardiol. 2020;76(13):1517\u201320. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.004.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"2282_CR26","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","volume":"123","author":"M Miller","year":"2011","unstructured":"Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292\u2013333. https:\/\/doi.org\/10.1161\/CIR.0b013e3182160726.","journal-title":"Circulation"},{"key":"2282_CR27","doi-asserted-by":"publisher","unstructured":"De la Maza-Bustindui NS, Le\u00f3n-\u00c1lvarez M, Ponce-Acosta C et al. Impact of cardiometabolic risk factors and its management on the reversion and progression of arterial stiffness. NPJ Cardiovasc Health. 2025;2(1):36. Published 2025 Jul 8. https:\/\/doi.org\/10.1038\/s44325-025-00074-6","DOI":"10.1038\/s44325-025-00074-6"},{"issue":"4","key":"2282_CR28","doi-asserted-by":"publisher","first-page":"100868","DOI":"10.1016\/j.jacadv.2024.100868","volume":"3","author":"CR Howell","year":"2024","unstructured":"Howell CR, Zhang L, Mehta T, et al. Cardiometabolic Disease Staging and Major Adverse Cardiovascular Event Prediction in 2 Prospective Cohorts. JACC Adv. 2024;3(4):100868. https:\/\/doi.org\/10.1016\/j.jacadv.2024.100868.","journal-title":"JACC Adv"},{"issue":"2","key":"2282_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/1346-8138.16201","volume":"49","author":"T Hamada","year":"2022","unstructured":"Hamada T, Morita A, Suga H, et al. Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: Real-world experience from post-marketing surveillance. J Dermatol. 2022;49(2):253\u201362. https:\/\/doi.org\/10.1111\/1346-8138.16201.","journal-title":"J Dermatol"},{"issue":"4","key":"2282_CR30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.det.2015.05.007","volume":"33","author":"AO Huen","year":"2015","unstructured":"Huen AO, Kim EJ. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. Dermatol Clin. 2015;33(4):715\u201329. https:\/\/doi.org\/10.1016\/j.det.2015.05.007.","journal-title":"Dermatol Clin"},{"issue":"6","key":"2282_CR31","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/bjd.21772","volume":"187","author":"G Roccuzzo","year":"2022","unstructured":"Roccuzzo G, Fava P, Avallone G, et al. Time to next treatment and safety assessment in cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin. Br J Dermatol. 2022;187(6):1019\u201321. https:\/\/doi.org\/10.1111\/bjd.21772.","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02282-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02282-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02282-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:03:25Z","timestamp":1786457005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02282-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2282"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02282-5","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study utilized de-identified aggregated data, an ethics approval was not required.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study utilized de-identified aggregated data, informed consent was waived.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study utilized de-identified aggregated data, specific institutional review board (IRB) approval was not required.","order":4,"name":"Ethics","label":"Institutional review board approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"295"}}